SERIES B COMMON STOCK PURCHASE WARRANT SORRENTO THERAPEUTICS, INC.Warrant Agreement • June 28th, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES A COMMON STOCK PURCHASE WARRANT SORRENTO THERAPEUTICS, INC.Series a Common Stock Purchase Warrant • June 28th, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [six months of the Issue Date] (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES C COMMON STOCK PURCHASE WARRANT SORRENTO THERAPEUTICS, INC.Series C Common Stock Purchase Warrant • June 28th, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [six months of the Issue Date] (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares of the Company’s Common Stock (as subject to adjustment hereunder, the “Warrant Shares”); provided, however, the exercisability of this Series C Warrant shall vest ratably from time to time in proportion to the Holder’s (or its permitted assigns) exercise in cash of the Series B Common Stock Purchase Warrant as compared with all Series B Common Stock Purchase Warrants issued to the Holder on the Issue Date (“Vesting Schedule”). B
8,333,334 Shares Series A Warrants to Purchase 8,333,334 Shares Series B Warrants to Purchase 8,333,334 Shares Series C Warrants to Purchase 8,333,334 Shares Sorrento Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 28th, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
Introductory. Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 8,333,334 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), (ii) warrants, substantially in the form of Annex A hereto (the “Series A Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.75 per share (the “Firm Series A Warrants”), (iii) warrants, substantially in the form of Annex B hereto (the “Series B Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.00 per share (the “Firm Series B Warrants”), and (iv) warrants, substantially in the form of Annex C hereto (the “Series C Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.75 per share (the “Firm Series C Warrants”, and toge
